167 related articles for article (PubMed ID: 26277594)
1. Continuing IgG replacement therapy for hypogammaglobulinemia after rituximab--for how long?
Barmettler S; Price C
J Allergy Clin Immunol; 2015 Nov; 136(5):1407-9. PubMed ID: 26277594
[No Abstract] [Full Text] [Related]
2. Intravenous versus subcutaneous immunoglobulin replacement in secondary hypogammaglobulinemia.
Spadaro G; Pecoraro A; De Renzo A; Della Pepa R; Genovese A
Clin Immunol; 2016 May; 166-167():103-4. PubMed ID: 27063866
[TBL] [Abstract][Full Text] [Related]
3. The Significance of B-cell Subsets in Patients with Unclassified Hypogammaglobulinemia and Association with Intravenous Immunoglobulin Replacement Requirement.
Karaman S; Erdem SB; Gülez N; Genel F
Iran J Immunol; 2018 Mar; 15(1):1-13. PubMed ID: 29549228
[TBL] [Abstract][Full Text] [Related]
4. Immunoglobulin G replacement for the treatment of infective complications of rituximab-associated hypogammaglobulinemia in autoimmune disease: a case series.
Roberts DM; Jones RB; Smith RM; Alberici F; Kumaratne DS; Burns S; Jayne DR
J Autoimmun; 2015 Feb; 57():24-9. PubMed ID: 25586449
[TBL] [Abstract][Full Text] [Related]
5. Hypogammaglobulinaemia.
Yong PF; Chee R; Grimbacher B
Immunol Allergy Clin North Am; 2008 Nov; 28(4):691-713, vii. PubMed ID: 18940570
[TBL] [Abstract][Full Text] [Related]
6. Rituximab-associated hypogammaglobulinemia: incidence, predictors and outcomes in patients with multi-system autoimmune disease.
Roberts DM; Jones RB; Smith RM; Alberici F; Kumaratne DS; Burns S; Jayne DR
J Autoimmun; 2015 Feb; 57():60-5. PubMed ID: 25556904
[TBL] [Abstract][Full Text] [Related]
7. Reconstitution of IgG Subclasses following Immunoglobulin Therapy in Adult Primary Hypogammaglobulinemia.
Sharma T; Gupta S
Int Arch Allergy Immunol; 2019; 180(3):221-232. PubMed ID: 31509832
[TBL] [Abstract][Full Text] [Related]
8. Profound hypogammaglobulinemia 7 years after treatment for indolent lymphoma.
Walker AR; Kleiner A; Rich L; Conners C; Fisher RI; Anolik J; Friedberg JW
Cancer Invest; 2008 May; 26(4):431-3. PubMed ID: 18443965
[TBL] [Abstract][Full Text] [Related]
9. Persistent hypogammaglobulinemia due to immunoglobulin class switch impairment by peri-transplant rituximab therapy.
Mizuhara K; Fujii N; Meguri Y; Takahashi T; Aoe M; Nakamura M; Seike K; Sando Y; Fujii K; Abe M; Sumii Y; Urata T; Fujiwara Y; Saeki K; Asada N; Ennishi D; Nishimori H; Matsuoka KI; Maeda Y
Int J Hematol; 2020 Sep; 112(3):422-426. PubMed ID: 32342335
[TBL] [Abstract][Full Text] [Related]
10. Hypogammaglobulinemia with decreased class-switched B-cells and dysregulated T-follicular-helper cells in IPEX syndrome.
Shamriz O; Patel K; Marsh RA; Bleesing J; Joshi AY; Lucas L; Prince C; Pencheva BB; Kobrynski L; Chandrakasan S
Clin Immunol; 2018 Dec; 197():219-223. PubMed ID: 30368009
[TBL] [Abstract][Full Text] [Related]
11. Association of Rituximab Use With Adverse Events in Children, Adolescents, and Young Adults.
McAtee CL; Lubega J; Underbrink K; Curry K; Msaouel P; Barrow M; Muscal E; Lotze T; Srivaths P; Forbes LR; Allen C; Bernhardt MB
JAMA Netw Open; 2021 Feb; 4(2):e2036321. PubMed ID: 33533931
[TBL] [Abstract][Full Text] [Related]
12. Consequences of B-cell-depleting therapy: hypogammaglobulinemia and impaired B-cell reconstitution.
Sacco KA; Abraham RS
Immunotherapy; 2018 Jun; 10(8):713-728. PubMed ID: 29569510
[TBL] [Abstract][Full Text] [Related]
13. Impact of trough IgG on pneumonia incidence in primary immunodeficiency: A meta-analysis of clinical studies.
Orange JS; Grossman WJ; Navickis RJ; Wilkes MM
Clin Immunol; 2010 Oct; 137(1):21-30. PubMed ID: 20675197
[TBL] [Abstract][Full Text] [Related]
14. Dysfunctional Immune System Reconstitution After Rituximab Exposure In Utero.
Clark R; Lindsey D; Whiteway S; Mikita C; Lieuw K
J Pediatr Hematol Oncol; 2021 May; 43(4):e601-e604. PubMed ID: 32590421
[TBL] [Abstract][Full Text] [Related]
15. Immunoglobulin replacement for secondary immunodeficiency after B-cell targeted therapies in autoimmune rheumatic disease: Systematic literature review.
Wijetilleka S; Mukhtyar C; Jayne D; Ala A; Bright P; Chinoy H; Harper L; Kazmi M; Kiani-Alikhan S; Li C; Misbah S; Oni L; Price-Kuehne F; Salama A; Workman S; Wrench D; Karim MY
Autoimmun Rev; 2019 May; 18(5):535-541. PubMed ID: 30844552
[TBL] [Abstract][Full Text] [Related]
16. Incidence of hypogammaglobulinemia in patients receiving rituximab and the use of intravenous immunoglobulin for recurrent infections.
Casulo C; Maragulia J; Zelenetz AD
Clin Lymphoma Myeloma Leuk; 2013 Apr; 13(2):106-11. PubMed ID: 23276889
[TBL] [Abstract][Full Text] [Related]
17. [Variable immune deficiency syndrome with antibody deficiency--long-term substitution with immunoglobulins].
Vaith P; Maas D
Immun Infekt; 1984 Apr; 12(2):123-8. PubMed ID: 6442916
[TBL] [Abstract][Full Text] [Related]
18. Rituximab Associated Hypogammaglobulinemia in Autoimmune Disease.
Tieu J; Smith RM; Gopaluni S; Kumararatne DS; McClure M; Manson A; Houghton S; Jayne DRW
Front Immunol; 2021; 12():671503. PubMed ID: 34054846
[TBL] [Abstract][Full Text] [Related]
19. Rituximab-induced hypogammaglobulinemia and infection risk in pediatric patients.
Labrosse R; Barmettler S; Derfalvi B; Blincoe A; Cros G; Lacombe-Barrios J; Barsalou J; Yang N; Alrumayyan N; Sinclair J; Ong MS; Camargo CA; Walter J; Haddad E
J Allergy Clin Immunol; 2021 Aug; 148(2):523-532.e8. PubMed ID: 33862010
[TBL] [Abstract][Full Text] [Related]
20. A Multicentre Study on the Efficacy, Safety and Pharmacokinetics of IqYmune®, a Highly Purified 10% Liquid Intravenous Immunoglobulin, in Patients with Primary Immune Deficiency.
Krivan G; Chernyshova L; Kostyuchenko L; Lange A; Nyul Z; Derfalvi B; Musial J; Bellon A; Kappler M; Sadoun A; Bernatowska E
J Clin Immunol; 2017 Aug; 37(6):539-547. PubMed ID: 28711959
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
